Pléase	type	a	olus	sian	1+	inelde	thie	hov	_
- regac	rype	•	pius	agn	١٣,	11112108	นแร	DOX	

E (110 0 7 20

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of

JR1			-	- 4
Ē/	Complete if Know	n 😟	,	778
Application Number	09/628,387		20	7
Filing Date	08/01/2000	Ū.	ינכל	V., J
First Named Inventor	Soon-Shiong			10
Group Art Unit	1615	20	ಆ	7
Examiner Name	A. Pulliam	60	00.	П
Attorney Docket Number	ART1150-18	(0712/3=0	12181	7

				U.S. PATENT DOCUMENTS		
U.S. Patent Document						
Examiner Initials	Doc. No.	Doc. Application or Kin No. Patent Number Co		Name of Patentee or Applicant	Date of Publication	Filing Date I Appropriate
AUP	1	6,096,331		Desai et al.	08/01/00	
	2	5,916,596		Desai et al.	06/29/99	
	3	5,665,382		Grinstaff et al.	09/09/97	
	4	5,498,421		Grinstaff et al.	03/12/96	
	5	5,439,686		Desai et al.	08/08/95	
i	6	5,362,478	1	Desai et al.	11/08/94	
	7	5,560,933		Soon-Shiong et al.	10/01/96	
1.	8	5,641,803		Carretta et al.	06/24/97	./
	9	5,001,235		Kim C	03/19/91	
	10	5,006,650		Barbachyn	04/09/91	
	11	5,015,737		Kim	05/14/91	
	12	5,416,071		Igari et al.	05/16/95	
	13	5,432,166		Peck et al.	07/11/95	· .
	14	5,434,143		Spielvogel et al.	07/18/95	
	15	5,442,062		Spielvogel et al. Koh et al.	08/15/95	
	16	5,457,119		Bonjouklian et al.	10/10/95	
	17	5,464,841		Portoghese et al.	11/07/95	
	18	5,464,865			11/07/95	
	19	5,468,480		Barrett et al.	11/21/95	
	20	5,468,741		Yen	11/21/95	
	21	5,616,320		Argoudelis et al.	04/01/97	
	22	6,020,368		Hinks et al.	02/02/00	
	23	6,218,377	B1	Stogniew et al.	04/17/01	
	24	6,218,426	B1	Anderson et al.	04/17/01	
	25	6,225,311	B1	Levin et al.	05/01/01	
	26	6,225,342	B1	Habtemarium et al.	05/01/01	
1/ 1	27	6,228,985	B1	Blood et al.	05/08/01	
	28	6,239,175	B1	Hinks et al.	05/29/01	

* A concise statement of relevance is being submitted in liquid a translation 27 CER 4 00(a)(2)

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus	; s sign (+) inside this box	→ `[]	01 P E MAR 0 7 200	SOLA BO		
	-	I MEETE.	To the state of th	.8/	Complete if Known	
Substitute for form 1449A/B/PTO				Application Number	09/628,387	70
INEC	RMATION	חופר	OSLIDE	Filing Date	08/01/2000	
_				First Named Inventor	Soon-Shiong	20 ∞
SIA	TEMENT B	r AP	LICANI	Group Art Unit	1615	8 8
	(Use as many sheet	s as nece	essary)	Examiner Name	A. Pulliam	25.0
Sheet	1	of	3	Attorney Docket Number	A. Pulliam ABI1150-18 (071243-0248)

OTHER - NON PATENT LITERATURE DOCUMENTS Framing: Doc Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,				slation
Examiner Initials	Doc. No.	magazine journal perial symposium estatos etc.) data paga(s) volume isque number (s) publicher eite		No*+
XU	O'Connell et al., Phase I Trial of Taxol Given As a Three Hour Infusion Every Three Weeks, 26 Proceedings of the AACR, 169 (Abstract 671) (1985) Longnecker et al., Phase I and Pharmacokinetic Study of Taxol in Patients with Advanced Cancer, 4 Proceedings of ASCO, 32 (C-119) (1985)			
	3	Donehower et al., <i>Phase I Trial of Taxol in Patients with Advanced Cancer</i> , 71 Cancer Treatment Reports, Vol. 71, No. 12, 1171-77 (Dec. 1987)	•	
	4	Waugh et al., Stability, compatability and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers, Am. J. Hosp. Pharm. Vol. 48, No. 7, 1520-24 (July, 1991)		
	5	Kris et al., Phase I Of Taxol Given As A 3-Hour Infusion Every 21 Days, 70 Cancer Treatment Reports, 605-607 (1986)		
	6	Rowinsky et al., <i>Phase II Study of Taxol in Advanced Ovarian Epithelial Malignancies</i> , 7 Proceedings of ASCO (523) (1988)		
	7	McGuire et al., Taxol: A Unique Antineoplastic Agent With Significant Activity In Advanced Ovarian Epithelial Neoplasms, 111 Annals of Internal Medicine 273-279 (1989)		
	8	Thigpen et al., Phase II Trial of Taxol as Second-Line Therapy for Ovarian Carcinoma: A Gynecologic Oncology Group Study, 9 Proceedings of ASCO (604) (1990)		
	9	Rowinsky, <i>Taxol: A Novel Investigational Antimicrotubule Agent</i> , 82 J. Nat. Canc. Inst. 1247-1258 (1990)		
	10	The American Heritage Dictionary of the English Language 553, 1987 (3d ed. 1992)		
	11	Remington's Pharmaceutical Sciences 1752-54 (18th ed. 1990)		_
	12	Physicians' Desk Reference 682-85 (49th ed. 1995)		
	13	Eisenhauer et al., European-Canadian Randomized Trial of Paclitaxel in Relapsed Ovarian Cancer: High-Dose Versus Low-Dose and Long Versus Short Infusion, J. Clin. Oncology, 2654-66 (Dec. 1994)		
	14	The United States Pharmacopeia 24 (Jan. 1, 2000), pp. 1-14 (General Notices And Requirements); 1775-1777 (<1> Injections); 1930-1936 (<661> Containers); 2107-2228 (<1151> Pharmaceutical Dosage Forms); 2143-2148 (<1211> Sterilization And Sterility Assurance Of Compendial Articles).		
	15	Physicians' Desk Reference, 55th ed. (2001), pp. 1059-1067		
	16	Dispensing of Medication (John E. Hoover ed., 8th ed. 1976), pp. 1-16 (ch. 1), 255-295 (ch. 10)		
	17	The Practice of Pharmacy, pp. 404-427, (Donald C. McLeod & William A. Miller eds., 1st ed. 1981)		
/	18	Remington: The Science and Practice of Pharmacy (20th ed.), pp. 780-806 (ch. 41), 807-820 (ch. 42), 1911-1931 (ch. 111)		_
J	19	Handbook of Institutional Pharmacy Practice (Mickey C. Smith & Thomas R. Brown eds., 1979) pp. 52-61, 257-289, 302-324, 620-634		

6	(P)	Ē	,		
X	497	2 6 2002 E	Practice Standards of ASHP 1996-1997, American Society of Health-System Pharmacists, Practice Standards of ASHP pp. 11, 18-20, 30-38, 96-102, 118-119, 130- 146, 165-175, 293-296	ECH	
E		2 18	Fundamentals of Nursing (LuVerne Wolff et al. eds., 6th ed.), pp. 597-644	0	MA MA
A PA	RADE	MERRY	Packaging Drugs and Pharmaceuticals (Wilmer A. Jenkins & Kenton R. Osborn eds.), pp. 1-9, 32-37, 54-65, 309-326, 332, 343	ENTER	R 1
		23	Bryony S. Dean et al., Comparison of medication errors in an American and a British Hospital, <i>Am. J. Health-Syst. Pharm.</i> 52, 2543-9 (1995)	1600	3 2007
		24	Harald O. Schwarz, Bret A. Brodowy, Implementation and Evaluation of an Automated Dispensing System, <i>Am. J. Health-Syst. Pharm.</i> 52, 823-828 (1995)	1600/2900	,
		25	John P. Santell, ASHP National Survey of Hospital-Based Pharmaceutical Services – 1994, <i>Am. J. Health-Syst. Pharm.</i> 52, 1179-1198 (1995)		
		26	Fred Puckett, Medication-Management Component of a Point-of-Care Information System, <i>Am. J. Health-Syst. Pharm.</i> 52, 1305-1309 (1995)		
		27	Neil J. Facchinetti et al., Evaluating Error Detection Rates in a Hospital Pharmacy, <i>Med. Care</i> 37, 39-43 (1999)		
		28	Joseph Perricone, William Hughes, Cost effective method of implementing decentralized unit dose pharmacy services in a Friesen setting, <i>Hospital Pharmacy</i> 19, 817-822 (1984)		
		29	Katja Taxis et al., Hospital drug distribution systems in the UK and Germany – a study of medication errors, <i>Pharmacy World & Science</i> 21, 25-31 (1999)		
		30	Compliance Policy Guides Manual, Human Drugs, Chapter 4, § 430.100 United Dose Labeling for Solid and Liquid Oral Dosage Forms (CPG 7132b.10) available at http://www.fda.gov/ora/compliance-ref/cpg/cpgdrg/cpg430-100.html		
		31	Dictionary of Pharmacy 74 (University of South Carolina Press) (1986)		
		32	12 Encyclopedia of Pharmaceutical Technology (James Swarbrick & James C. Boylan eds., 1995)		
		33	William E. Hassan, Jr., Hospital Pharmacy 278-94 (5th ed. 1986)		
		34	Human Drugs, Compliance Policy Guides Manual ch. 4, § 480.200, at http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg480-200.html (August 2001)		
		35	Guidelines for Unit Dose Dispensing, Arizona Board of Pharmacy Substantive Policies, available at http://www.pharmacy.state.az.us/link69.htm		
		36	Healthcare Compliance Packaging Council, available at http://www.unitdose.org/ (Glossary of Pharmaceutical Packaging Terms, Healthcare Compliance Packaging Council, available at http://www.unitdose.org/glossary.htm		
		37	Clarence W. Taber, Taber's Cyclopedic Medical Dictionary 1941 (16th ed. 1989)		
		38	Thomas J. Garrison, <i>Medication Distribution Systems</i> , Handbook of Institutional Pharmacy Practice ch. IV.1, 259 (Mickey C. Smith & Thomas R. Brown eds., 1979)		
		39	Ken Harms & F. Mauriece Smith, <i>Packaging Pharmaceuticals in Institutions</i> , Handbook of Institutional Pharmacy Practice ch. IV.6, 302 (Mickey C. Smith & Thomas R. Brown eds., 1979)		
		40	Clyde Buchanan, <i>Unit Dose Drug Distribution</i> , The Practice of Pharmacy ch. 33, 404 (Donald C. McLeod & William A. Miller eds.) (1st ed. 1981)		
	-	41	ASHP Technical Assistance Bulletin on Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages, Practice Standards of American Society of Health-System Pharmacists 118-19 (1996-1997)		
		42	ASHP Statement on Unit Dose Drug Distribution, Practice Standards of American Society of Health-System Pharmacists 11 (1996-1997)		
	,	43	Marc R. Summerfield, <i>Unit Dose Primer</i> 9-10 (1983)		
		44	James C. Boylan et al., <i>Parenteral Products</i> , Modern Pharmaceutics, ch. 12, 441-87 (Gilbert S. Banker & Christopher T. Rhodes eds.) (3rd ed. 1996)		

>

_	,		▼″	
	*	45	Best Practices for Health-System Pharmacy, American Society of Health-System Pharmacists (2000-2001 ed.), pp. 42-57, 85, 87-97	
	+	46	The Pink Sheet 55(1): 8-9 (January 4, 1993)	

Examiner Signature	Date Considered 5/14	102

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).